BRIEF published on 08/08/2025 at 23:35, 6 months 11 days ago La FDA approuve le système Genio® de Nyxoah pour le traitement de l'apnée obstructive du sommeil Approbation De La FDA Nyxoah Apnée Obstructive Du Sommeil Commercialisation Aux États-Unis Système Genio
PRESS RELEASE published on 08/08/2025 at 23:30, 6 months 11 days ago Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea Nyxoah receives FDA approval for Genio System, advancing OSA treatment with bilateral stimulation and leadless technology. U.S. commercialization launched FDA Approval Nyxoah Obstructive Sleep Apnea Neuromodulation Genio System
BRIEF published on 07/28/2025 at 22:10, 6 months 22 days ago Nyxoah’s DREAM Study Data Featured in Clinical Journal Obstructive Sleep Apnea DREAM Study Clinical Outcomes Genio® System Patient Satisfaction
BRIEF published on 07/28/2025 at 22:10, 6 months 22 days ago Les données de l'étude DREAM de Nyxoah présentées dans une revue clinique Résultats Cliniques Apnée Obstructive Du Sommeil Étude DREAM Système Genio® Satisfaction Des Patients
PRESS RELEASE published on 07/28/2025 at 22:05, 6 months 22 days ago Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine Nyxoah's DREAM pivotal study data on Genio system for OSA treatment published in Journal of Clinical Sleep Medicine. Study shows high patient satisfaction & improved quality of life Sleep Medicine Nyxoah Genio System DREAM Pivotal Study OSA Treatment
BRIEF published on 05/14/2025 at 07:05, 9 months 6 days ago Nyxoah Reports First Quarter 2025 Financial and Operating Results Financial Results FDA Approval Nyxoah Q1 2025 Genio System
BRIEF published on 05/14/2025 at 07:05, 9 months 6 days ago Nyxoah publie ses résultats financiers et opérationnels du premier trimestre 2025 Résultats Financiers Approbation De La FDA Nyxoah Système Genio T1 2025
PRESS RELEASE published on 05/14/2025 at 07:00, 9 months 6 days ago Nyxoah Reports First Quarter Financial and Operating Results Nyxoah reports financial and operating results for the first quarter of 2025, including progress towards FDA PMA approval for the Genio® system. Revenue €1.1 million. Cash position €63.0 million Financial Results FDA Approval Operating Highlights Nyxoah Genio® System
BRIEF published on 04/08/2025 at 07:05, 10 months 12 days ago Nyxoah informe sur le processus d'approbation du système Genio par la FDA Technologie Médicale Approbation De La FDA Nyxoah Apnée Obstructive Du Sommeil Système Genio
BRIEF published on 04/08/2025 at 07:05, 10 months 12 days ago Nyxoah Updates on FDA Approval Process for Genio System FDA Approval Medical Technology Nyxoah Obstructive Sleep Apnea Genio System
Published on 02/20/2026 at 18:30, 18 minutes ago Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 3 hours 3 minutes ago Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 4 hours 18 minutes ago Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant
Published on 02/20/2026 at 14:08, 4 hours 40 minutes ago Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange
Published on 02/20/2026 at 14:00, 4 hours 48 minutes ago Nextech3D.ai's Eventdex Platform Powers AI Matchmaking for the SBA's CT Business Matchmaker Event Featuring Government Agencies and Major Prime Contractors
Published on 02/20/2026 at 18:36, 12 minutes ago EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 17 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:00, 48 minutes ago Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 48 minutes ago Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations
Published on 02/20/2026 at 09:28, 9 hours 20 minutes ago Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 31 janvier 2026
Published on 02/20/2026 at 09:28, 9 hours 20 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of January 31, 2026
